Fate Therapeutics (FATE) EBIT Margin (2012 - 2026)
Fate Therapeutics' (FATE) quarterly EBIT Margin came in at 2540.42% in Q1 2026, down 635.0% YoY from 474.84% in Q1 2025, and little changed on a QoQ basis from 2536.23% in Q4 2025.
Fate Therapeutics (FATE) EBIT Margin (2012 - 2026) Analysis & Trends
Fate Therapeutics (FATE) has 14 years of EBIT Margin data on file, last reported at 2540.42% in Q1 2026.
- Quarterly EBIT Margin fell 635.0% year-over-year to 2540.42% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 2207.47% (down 70400.0% YoY) and the FY2025 annual result came in at 2222.45%, down 67982.0% from the prior year.
- EBIT Margin held at 2540.42% in Q1 2026, from 2536.23% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 48.48% in Q1 2023 to a low of 6705.79% in Q2 2023.
- A 5-year average of 1983.62% and a median of 1995.12% in 2025 frame the typical range for EBIT Margin.
- Annual changes were most pronounced in 2023 — EBIT Margin plunged 625774 bps — and 2024, when it soared 604006 bps.
- Tracing FATE's EBIT Margin over 5 years: stood at 145.23% in 2022, then slumped by 1875 bps to 2868.44% in 2023, then fell by 16 bps to 3319.78% in 2024, then grew by 24 bps to 2536.23% in 2025, then fell by 0 bps to 2540.42% in 2026.
- The last three EBIT Margin figures came in at 2540.42% (Q1 2026), 2536.23% (Q4 2025), and 1995.12% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -105.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Fate Therapeutics | 298.82 Mn | 298.82 Mn | - | -2,540.42% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,540.42% |
| Dec 31, 2025 | -2,536.23% |
| Sep 30, 2025 | -1,995.12% |
| Jun 30, 2025 | -1,938.54% |
| Mar 31, 2025 | -2,534.07% |
| Dec 31, 2024 | -3,319.78% |
| Sep 30, 2024 | -1,703.87% |
| Jun 30, 2024 | -665.73% |
| Mar 31, 2024 | -2,652.88% |
| Dec 31, 2023 | -2,868.44% |
| Sep 30, 2023 | -2,637.81% |
| Jun 30, 2023 | -6,705.79% |
| Mar 31, 2023 | -48.48% |
| Dec 31, 2022 | -145.23% |
| Sep 30, 2022 | -576.67% |
| Jun 30, 2022 | -448.05% |
| Mar 31, 2022 | -404.40% |
| Dec 31, 2021 | -406.48% |
| Sep 30, 2021 | -383.99% |
| Jun 30, 2021 | -348.78% |